|
Malignant neoplasm of prostate
|
0.190 |
GeneticVariation
|
disease |
GWASDB |
Multiple newly identified loci associated with prostate cancer susceptibility.
|
18264097 |
2008 |
|
Prostatic Neoplasms
|
0.010 |
AlteredExpression
|
group |
BEFREE |
Our aim in this present study was the specific quantitative expression analysis of the classical KLK15 mRNA transcript in prostate tumors and the examination of its clinical significance in prostate cancer.
|
23620432 |
2013 |
|
Malignant neoplasm of prostate
|
0.190 |
AlteredExpression
|
disease |
BEFREE |
Our aim in this present study was the specific quantitative expression analysis of the classical KLK15 mRNA transcript in prostate tumors and the examination of its clinical significance in prostate cancer.
|
23620432 |
2013 |
|
Prostate carcinoma
|
0.090 |
AlteredExpression
|
disease |
BEFREE |
Our aim in this present study was the specific quantitative expression analysis of the classical KLK15 mRNA transcript in prostate tumors and the examination of its clinical significance in prostate cancer.
|
23620432 |
2013 |
|
Asthma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Patients with ACO generally had the highest medication costs of any cohort (long-acting muscarinic antagonist costs ranged from $227/patient [asthma cohort] to $349/patient [ACO cohort]); they also experienced more respiratory-related hospital visits than patients with asthma or COPD (mean outpatient/inpatient visits per patient post-index: 9.1/1.9 [ACO cohort] vs 5.7/1.4 [asthma cohort] and 6.4/1.7 [COPD cohort]).
|
29368608 |
2018 |
|
Chronic Obstructive Airway Disease
|
0.010 |
Biomarker
|
disease |
BEFREE |
Patients with ACO generally had the highest medication costs of any cohort (long-acting muscarinic antagonist costs ranged from $227/patient [asthma cohort] to $349/patient [ACO cohort]); they also experienced more respiratory-related hospital visits than patients with asthma or COPD (mean outpatient/inpatient visits per patient post-index: 9.1/1.9 [ACO cohort] vs 5.7/1.4 [asthma cohort] and 6.4/1.7 [COPD cohort]).
|
29368608 |
2018 |
|
asthma with copd
|
0.020 |
Biomarker
|
disease |
BEFREE |
Patients with both disease features (asthma-COPD overlap [ACO]) are common.
|
29713158 |
2018 |
|
Malignant neoplasm of prostate
|
0.190 |
Biomarker
|
disease |
BEFREE |
Previous studies implied a role of KLK15 in prostate cancer.
|
29958881 |
2018 |
|
Prostate carcinoma
|
0.090 |
Biomarker
|
disease |
BEFREE |
Previous studies implied a role of KLK15 in prostate cancer.
|
29958881 |
2018 |
|
Benign Neoplasm
|
0.010 |
AlteredExpression
|
group |
BEFREE |
Quantified KLK15 gene expression levels discriminate prostate cancer from benign tumors and constitute a novel independent predictor of disease progression.
|
23620432 |
2013 |
|
Malignant neoplasm of breast
|
0.320 |
Biomarker
|
disease |
BEFREE |
Several lines of evidence suggest that members of the kallikrein family are involved in various malignancies such as prostate (PSA, KLK2, KLK15), ovarian (KLK4, KLK5, KLK6, KLK8, KLK10), and breast cancer (KLK10, KLK13, KLK14).
|
12633763 |
2003 |
|
Breast Carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Several lines of evidence suggest that members of the kallikrein family are involved in various malignancies such as prostate (PSA, KLK2, KLK15), ovarian (KLK4, KLK5, KLK6, KLK8, KLK10), and breast cancer (KLK10, KLK13, KLK14).
|
12633763 |
2003 |
|
Malignant neoplasm of prostate
|
0.190 |
Biomarker
|
disease |
BEFREE |
The KLK15 splice variant appears to be a candidate biomarker for prostate cancer.
|
15650036 |
2005 |
|
Prostate carcinoma
|
0.090 |
Biomarker
|
disease |
BEFREE |
The KLK15 splice variant appears to be a candidate biomarker for prostate cancer.
|
15650036 |
2005 |
|
Malignant neoplasm of breast
|
0.320 |
Biomarker
|
disease |
BEFREE |
The androgen-regulated gene human kallikrein 15 (KLK15) is an independent and favourable prognostic marker for breast cancer.
|
12439720 |
2002 |
|
Mammary Neoplasms
|
0.010 |
AlteredExpression
|
group |
LHGDN |
The androgen-regulated gene human kallikrein 15 (KLK15) is an independent and favourable prognostic marker for breast cancer.
|
12439720 |
2002 |
|
Malignant Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
The kallikrein gene family (KLK1-KLK15) is the largest contiguous group of protease genes within the human genome and is associated with both risk and outcome of cancer and other diseases.
|
23894413 |
2013 |
|
Primary malignant neoplasm
|
0.040 |
Biomarker
|
group |
BEFREE |
The kallikrein gene family (KLK1-KLK15) is the largest contiguous group of protease genes within the human genome and is associated with both risk and outcome of cancer and other diseases.
|
23894413 |
2013 |
|
ovarian neoplasm
|
0.020 |
AlteredExpression
|
disease |
LHGDN |
The purpose of this study was to examine the prognostic value of KLK15 in ovarian cancer tissues.
|
12915603 |
2003 |
|
Secondary malignant neoplasm of lymph node
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
There was no significant correlation between either KLK11 or KLK15 expression and the presence of lymph node metastases or Lauren classification (intestinal vs. diffuse).
|
26224476 |
2016 |
|
Benign Prostatic Hyperplasia
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
These results suggest that KLK15 expression analysis could be employed as a valuable tool for the discrimination between BPH and CaP tissue specimens and as an unfavorable prognostic marker for prostate cancer.
|
20067463 |
2010 |
|
Malignant neoplasm of prostate
|
0.190 |
AlteredExpression
|
disease |
BEFREE |
These results suggest that KLK15 expression analysis could be employed as a valuable tool for the discrimination between BPH and CaP tissue specimens and as an unfavorable prognostic marker for prostate cancer.
|
20067463 |
2010 |
|
Prostate carcinoma
|
0.090 |
AlteredExpression
|
disease |
BEFREE |
These results suggest that KLK15 expression analysis could be employed as a valuable tool for the discrimination between BPH and CaP tissue specimens and as an unfavorable prognostic marker for prostate cancer.
|
20067463 |
2010 |
|
Asthma
|
0.020 |
Biomarker
|
disease |
BEFREE |
This post hoc analysis of a randomized, double-blind, parallel-arm trial (GSK ID: 200699; NCT02164539) assessed the structure, reliability, validity and responsiveness of the E-RS, and a separate wheeze item, for use in patients with a primary diagnosis of asthma or COPD, but with spirometric characteristics of both (fixed airflow obstruction and reversibility to salbutamol; a subset of patients referred to as spirometric asthma-COPD overlap [ACO]; N = 338).
|
31151458 |
2019 |
|
asthma with copd
|
0.020 |
Biomarker
|
disease |
BEFREE |
This post hoc analysis of a randomized, double-blind, parallel-arm trial (GSK ID: 200699; NCT02164539) assessed the structure, reliability, validity and responsiveness of the E-RS, and a separate wheeze item, for use in patients with a primary diagnosis of asthma or COPD, but with spirometric characteristics of both (fixed airflow obstruction and reversibility to salbutamol; a subset of patients referred to as spirometric asthma-COPD overlap [ACO]; N = 338).
|
31151458 |
2019 |